Clopidogrel improves microvascular endothelial function in subjects with stable coronary artery disease

Scott R Willoughby, Lee-Jen Luu, James Donald Cameron, Adam J Nelson, Carlee D Schultz, Stephen Grant Worthley, Matthew I Worthley

Research output: Contribution to journalArticleResearchpeer-review

18 Citations (Scopus)

Abstract

Background: Clopidogrel therapy has recently been shown to reduce cardiovascular events in patients with stable vascular disease. This benefit may be due to effects not exclusively related to platelet aggregation. The aim of this study was to evaluate the effect of clopidogrel therapy on microvascular endothelial function in subjects with stable coronary artery disease (CAD). Methods and Results: Forty subjects with stable CAD were randomised to clopidogrel therapy (75 mg/day) or control. Blood and endothelial function testing occurred at baseline, one week and three months following randomisation. Microvascular endothelial function was assessed via reactive hyperaemic index (RHI). Platelet function was assessed by adenosine diphosphate (ADP)-induced whole blood aggregation and the VerifyNow? system. Plasma markers of endothelial function (asymmetric dimethylarginine, ADMA) and oxidative stress (myeloperoxidase, MPO) were also tested. The primary endpoint was endothelial function assessment (RHI) at three months. At one week RHI increased by 20?10 in the clopidogrel group; this effect was maintained at three months (21?9 increase from baseline, P
Original languageEnglish
Pages (from-to)534 - 541
Number of pages8
JournalHeart Lung and Circulation
Volume23
Issue number6
DOIs
Publication statusPublished - 2014

Cite this